EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI

Bruna Victorasso Jardim-Perassi iD, Pietro Irrera iD, Justin Y C Lau iD, Mikalai Budzevich iD, Christopher J Whelan iD, Dominique Abrahams, Epifanio Ruiz, Arig Ibrahim-Hashim iD, Sultan Damgaci Erturk, Dario Livio Longo iD, Shari A Pilon-Thomas iD, Robert J Gillies iD

Contrast Media & Molecular Imaging · 05.01.2023 · 2023 · 1-12

DOI: 10.1155/2023/1944970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contrast Media & Molecular Imaging, erschienen am 05.01.2023. Verfasst von Bruna Victorasso Jardim-Perassi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Iopamidol, Pancreatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, and an altered metabolic state is often associated with malignancy. It has been shown that acidosis can promote tumor progression; thus, many therapeutic strategies have been adopted against tumor metabolism; one of these involves alkalinization therapies to raise tumor pH to inhibit tumor progression, improve immune surveillance, and overcome resistance to chemotherapies. Chemical exchange saturation transfer-magnetic resonance imaging (CEST-MRI) is a noninvasive technique that can measure pH in vivo using pH-sensitive contrast agents. Iopamidol, an iodinated contrast agent, clinically used for computed tomography (CT), contains amide group protons with pH-dependent exchange rates that can reveal the pHe of the tumor microenvironment. In this study, we optimized intraperitoneal (IP) delivery of iopamidol to facilitate longitudinal assessments of orthotopic pancreatic tumor pHe by CEST-MRI. Following IV-infusion and IP-bolus injections, we compared the two protocols for assessing tumor pH. Time-resolved CT imaging was used to evaluate the uptake of iopamidol in the tumor, revealing that IP-bolus delivered a high amount of contrast agent 40 min postinjection, which was similar to the amounts reached with the IV-infusion protocol. As expected, both IP and IV injection protocols produced comparable measurements of tumor pHe, showing no statistically significant difference between groups ( p = 0.16 ). In addition, we showed the ability to conduct longitudinal monitoring of tumor pHe using CEST-MRI with the IP injection protocol, revealing a statistically significant increase in tumor pHe following bicarbonate administration ( p < 0.001 ). In conclusion, this study shows the capability to measure pHe using an IP delivery of iopamidol into orthotopic pancreatic tumors, which is important to conduct longitudinal studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IopamidolPancreatic NeoplasmsHumansContrast MediaHydrogen-Ion ConcentrationMagnetic Resonance ImagingTumor Microenvironment

Substanzen

IopamidolContrast Media

Autor:innen und Institutionen

  • Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Small Animal Imaging Laboratory, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Biological Sciences, University of Illinois, Chicago, IL, USA.
  • Comparative Medicine, University of South Florida, Tampa, FL, USA.
  • Institute of Biostructures and Bioimages (IBB), National Research Council of Italy (CNR), Turin, Italy.
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

ORCID-Profile: Bruna Victorasso Jardim-Perassi, Pietro Irrera, Justin Y C Lau, Mikalai Budzevich, Christopher J Whelan, Arig Ibrahim-Hashim, Dario Livio Longo, Shari A Pilon-Thomas, Robert J Gillies

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Jardim-Perassi, B. V., Irrera, P., Lau, J. Y. C., Budzevich, M., Whelan, C. J., Abrahams, D., Ruiz, E., Ibrahim-Hashim, A., Damgaci Erturk, S., Longo, D. L., Pilon-Thomas, S. A., & Gillies, R. J. (2023). Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI. Contrast Media & Molecular Imaging, 2023, 1-12. https://doi.org/10.1155/2023/1944970

Vancouver

Jardim-Perassi BV, Irrera P, Lau JYC, Budzevich M, Whelan CJ, Abrahams D, et al. Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI. Contrast Media & Molecular Imaging. 2023;2023:1-12. doi:10.1155/2023/1944970

BibTeX
@article{JardimPerassi2023,
  author = {Jardim-Perassi, Bruna Victorasso and Irrera, Pietro and Lau, Justin Y C and Budzevich, Mikalai and Whelan, Christopher J and Abrahams, Dominique and Ruiz, Epifanio and Ibrahim-Hashim, Arig and Damgaci Erturk, Sultan and Longo, Dario Livio and Pilon-Thomas, Shari A and Gillies, Robert J},
  title = {Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI},
  journal = {Contrast Media & Molecular Imaging},
  year = {2023},
  volume = {2023},
  pages = {1--12},
  doi = {10.1155/2023/1944970}
}
Kostenlos starten →